Cagrilintide

卡瑞林肽

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameCagrilintide
Drug Alias NameAmylin analogue卡格列肽NN-9838NNC0174-0833
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAmylin receptor agonists
TargetsAmylin Receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[9
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[45
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[8
Inactive IndicationsNutritional and Metabolic Diseases

Other Information

ATC CodeN/A
Related LinksN/A